Literature DB >> 2436674

5-HIAA and HVA in CSF in patients with idiopathic pain disorders.

B G Almay, J Häggendal, L von Knorring, L Oreland.   

Abstract

Patients with idiopathic pain syndromes were compared with healthy volunteers and with patients suffering from chronic pain syndromes of neurogenic origin, with respect to the concentrations of the metabolites 5-hydroxy-indole-acetic acid (5-HIAA) and homovanillic acid (HVA) in cerebrospinal fluid (CSF). Patients with idiopathic pain syndromes were subdivided according to the presence or absence of somatic lesions. It was found that these groups did not differ in concentrations of 5-HIAA or HVA, at least not when values were corrected for age, sex, and body height. Patients with idiopathic pain syndromes were found to have low concentrations of 5-HIAA, but not of HVA, in CSF. These differences were also obvious when the values were corrected for age, sex, and body height. As low concentrations of 5-HIAA in CSF have previously been demonstrated in patients with depressive disorders, our results support the suggestion by Blumer and Heilbronn (1982) that the idiopathic pain syndrome is a variant of depressive disease. At least the two syndromes share a common pathogenetic mechanism--a disturbance in serotonergic turnover.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2436674     DOI: 10.1016/0006-3223(87)90162-4

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  11 in total

1.  [Substance P, somatostatin and monoaminergic transmitters in the cerebrospinal fluid of patients with chronic idiopathic trigeminal neuralgia].

Authors:  M Strittmatter; M Grauer; E Isenberg; G Hamann; C Fischer; K H Hoffmann; F Blaes; K Schimrigk
Journal:  Schmerz       Date:  1996-10-28       Impact factor: 1.107

2.  Platelet MAO in patients with idiopathic pain disorders.

Authors:  B G Almay; L von Knorring; L Oreland
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

3.  Monoamines in the brain cerebrospinal fluid of facial pain patients.

Authors:  A J Bouckoms; W H Sweet; C Poletti; P Lavori; D Carr; W Matson; P Gamache; N Aronin
Journal:  Anesth Prog       Date:  1992

4.  [Monoaminergic transmitters in the cerebrospinal fluid of patients with acute, chronic, and intermittent pain. Interface between pain and depression?].

Authors:  M Strittmatter; D Ostertag; K H Hoffmann; C Paulus; C Fischer; S Meyer
Journal:  Nervenarzt       Date:  2005-04       Impact factor: 1.214

5.  Urapidil permeates the intact blood-brain barrier.

Authors:  G Castor; U Schmidt
Journal:  Intensive Care Med       Date:  1994       Impact factor: 17.440

6.  Discrimination of idiopathic pain syndromes from neurogenic pain syndromes and healthy volunteers by means of clinical rating, personality traits, monoamine metabolites in CSF, serum cortisol, platelet MAO and urinary melatonin.

Authors:  L von Knorring; B G Almay; J Häggendal; F Johansson; L Oreland; L Wetterberg
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1986

7.  Association of NAG levels with specific psychiatric symptoms in unipolar patients.

Authors:  M J Garvey; M Noel
Journal:  J Psychiatry Neurosci       Date:  1995-01       Impact factor: 6.186

Review 8.  Idiopathic pain and depression.

Authors:  L von Knorring; L Ekselius
Journal:  Qual Life Res       Date:  1994-12       Impact factor: 4.147

9.  Alteration of serotonin transporter density and activity in fibromyalgia.

Authors:  Laura Bazzichi; Gino Giannaccini; Laura Betti; Giovanni Mascia; Laura Fabbrini; Paola Italiani; Francesca De Feo; Tiziana Giuliano; Camillo Giacomelli; Alessandra Rossi; Antonio Lucacchini; Stefano Bombardieri
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

10.  Clinical relevance of depressed kynurenine pathway in episodic migraine patients: potential prognostic markers in the peripheral plasma during the interictal period.

Authors:  Bernadett Tuka; Aliz Nyári; Edina Katalin Cseh; Tamás Körtési; Dániel Veréb; Ferenc Tömösi; Gábor Kecskeméti; Tamás Janáky; János Tajti; László Vécsei
Journal:  J Headache Pain       Date:  2021-06-25       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.